Aditxt Subsidiary Pearsanta Initiates Clinical Study for Novel Blood-Based Endometriosis Test
TL;DR
Aditxt's subsidiary Pearsanta offers investors early access to a novel blood test that could disrupt the $10B endometriosis market with non-invasive diagnostics.
Pearsanta's clinical study compares the Mitomic Endometriosis Test against laparoscopic diagnosis across 1,000 participants to validate its accuracy through systematic data collection.
This non-invasive blood test enables earlier endometriosis detection, reducing surgical risks and improving women's health outcomes through accessible diagnostic innovation.
Aditxt's blood test detects endometriosis markers years before symptoms appear, revolutionizing women's healthcare with cutting-edge molecular diagnostics.
Found this article helpful?
Share it with your network and spread the knowledge!
Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has begun recruiting participants for the clinical validation study. Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis, potentially transforming how the condition is diagnosed and managed.
Endometriosis currently requires laparoscopic surgery for definitive diagnosis, an invasive procedure that can delay treatment and diagnosis for many patients. The blood-based MET test represents a significant advancement in women's health diagnostics, offering the potential for earlier intervention and improved patient outcomes. The clinical study represents a critical step toward validating this innovative approach to endometriosis detection. Aditxt operates as a social innovation platform advancing health innovations across multiple programs, including women's health, autoimmunity, cancer and early disease detection, and infectious diseases. The company's latest news and updates are available in its newsroom at https://ibn.fm/ADTX. The full press release detailing the clinical study initiation can be viewed at https://ibn.fm/WiIhM.
The initiation of this large-scale clinical study marks an important development in women's healthcare, addressing a significant unmet need in endometriosis diagnosis. If successfully validated, the blood-based test could provide millions of women worldwide with a less invasive, more accessible diagnostic option for a condition that often takes years to properly diagnose using current methods. This advancement matters because endometriosis affects approximately 10% of reproductive-age women globally, yet diagnosis typically takes 7-10 years due to reliance on invasive surgical confirmation. The MET test could dramatically reduce this diagnostic delay, enabling earlier treatment that may prevent disease progression, reduce chronic pain, and improve fertility outcomes. By offering a simple blood test alternative to surgery, this innovation could democratize access to accurate diagnosis, particularly in underserved regions where surgical facilities are limited. The study's validation against the laparoscopic gold standard is crucial for establishing clinical credibility and regulatory approval pathways. Successful implementation could shift endometriosis diagnosis from hospital operating rooms to primary care settings, fundamentally changing clinical practice and patient experience while reducing healthcare costs associated with delayed diagnosis and unnecessary procedures.
Curated from InvestorBrandNetwork (IBN)
